There are many investment opportunities available for people to invest. The common investments may be of two categories – equity-oriented investments are market linked and contribute to equity capital of businesses, while debt-oriented investments are non-linked and invest in fixed-return instruments.

There are capital risks involved in equity-oriented investments, but along with the risks, the prospect of getting superior return is there in comparison to debt-oriented investments.

On the other hand, the risk of losing the capital invested is technically not there in the debt-oriented investments, but the prospect of earning higher return than the the pre-decided rate of return is absent.

Although many traditional investment instruments are available in both equity-oriented and debt-oriented categories, but most of them have generalised investment patterns and individual investors have little say in portfolio compositions.

With large amounts to invest, High Net worth Individuals (HNIs), however, want their say on investment management to generate superior returns by investing in niche segments, which are otherwise out of bound for traditional investment products due to higher regulatory controls.

“Alternative Investment Funds are an avenue to pool in funds for investing in private equity, real estate or hedge funds,” said Nitin Rao CEO InCred Wealth.

As described by Rao, there are 3 categories of AIFs :

Category I AIF are those funds that invest in start-ups or social venture funds, infrastructure funds, SME funds, and so on. The government or regulators consider this category of funds as socially viable or economically desirable.
Category II Funds are those that do not leverage or borrow, other than to meet the day-to-day operational requirements. This category typically consists of Private Equity Funds and Debt funds.
Category III funds typically comprised of Hedge Funds that employ diverse or complex trading strategies. By investing in listed or unlisted derivatives, AIF managers try to employ leverage.
“Generally, having significant previous experience in handling entrepreneurial funds and/or Mutual Funds, AIF fund managers tend to bring more experience than MF managers, to bring in better management and innovation,” said Rao.

So, AIFs provide HNIs opportunities to generate superior returns through customised investments.

However, with lower regulatory control and interventions, AIFs carry more risks compared to MFs and other traditional investments.

“It must be noted that by nature AIFs carry more risk, have a lock-in period and require time for the strategy to play out. As a result, they are suitable only for those who are willing to wait for the innovative theme to play out and carry the risk for such time. Investors should invest in AIFs only if their risk profile aligns with this expectation,” said Rao.

Cautioning the HNIs on the higher risk factor, Rao said, “In terms of allocation to AIFs, the overall portfolio allocation to the underlying asset is important to keep in mind, however it would be prudent to not to go beyond 5 per cent in a non-traditional AIF in a single name.”

Leave a comment

Vijay Gomatam

Consultant – Investment Banking

Vijay Gomatam has over 20 years of banking experience across M&A, corporate finance, capital markets, and corporate banking, with a strong focus on cross-border deal origination and execution across India, Southeast Asia, Japan, and Australia. He has deep sector expertise in industrials, IT services, media, and telecom, with extensive experience in India - Southeast Asia and India–Japan transactions. Vijay previously served as Director at MUFG Bank, Singapore, where he led the India - Japan M&A corridor, and earlier worked with Deutsche Bank, Merrill Lynch, Houlihan Lokey, and Edelweiss Alternative Asset Advisors.

His transaction experience includes Motherson Group’s acquisition of TSE-listed Yachiyo Industries, Takahata India’s stake sale to SPRL, Toppan Form’s acquisition of PT RDS in Indonesia, Mitsui’s investment in FKS Food & Agri, CVC’s investment in PT LinkNet, and capital market transactions for Southeast Asian media and telecom clients including SingTel, Axiata, and Bakrie Group.

He holds an MBA from IIM Calcutta and a B.E. (Hons.) from Nanyang Technological University, Singapore.

Akbar Khan

Senior Advisor – Investment Banking

Akbar Khan has over twenty years of experience across M&A advisory, Private Equity, and Corporate M&A, along with a decade as an entrepreneur and operator. He has held senior roles at Bank of America Merrill Lynch in India and London, where he led Telecom & Technology Investment Banking, Private Equity coverage, and M&A, and at General Electric, where he served as Head of Corporate Development and M&A for India and the MENA region. He has advised global corporates and financial sponsors including Reuters Plc, Telecom Italia, Hellenic Telecom, MTN, Tata Group, Apax Partners, Warburg Pincus, and TA Associates, and has led several notable transactions. These include advising E2E Networks on

its USD 50M capital raise, QuEST Global on its USD 75M Series B private placement to Warburg Pincus, Rain Technologies on its USD 65M Series A financing from QED Investors and Invus, Augnito.ai on its Pre-Series A raise from Apollo Hospitals Group, Tata Consultancy Services on the acquisition of Citigroup’s captive back-office unit, Forthnet in Greece on the acquisition of Netmed, and Telecom Italia on the sale of Cosmote via a leveraged buyout by Apax Partners and TPG.

In addition, Akbar co-founded and served as CEO of Rain Technologies India an earned wage access fintech platform.

He holds an MBA from London Business School and is a UK-qualified Chartered Accountant.

Shreyan ML

Managing Director – Healthcare & Pharma

Shreyan ML leads the healthcare and pharma investment banking practice and brings over 15 years of experience across investment banking, corporate M&A, and management consulting within the pharmaceutical sector. Prior to joining MAPE, he worked with Spark Capital, Strides Group, Wanbury Limited, and Tata Strategic Management Group.

His deal experience includes advising Curatio Healthcare on the sale of its business to Torrent Pharmaceuticals; Sale of TTK’s human pharma business to Bharat Serums; Glenmark Pharmaceuticals on the sale of the Razel brand to KKR-backed JB Chemicals & Pharma and the sale of nine dermatology brands to Eris Oaknet.

As Corporate M&A Head at Strides Group, he was involved in thesale of Agila to Mylan and led the animal health strategy at Sequent Scientific, executing over 12 transactions including fundraises and cross-border acquisitions.

He holds an MBA from IIM Indore and is a computer engineer from NIT Karnataka.

Arjun Mukherjee

Managing Director – Investment Banking

Arjun Mukherjee brings over 20 years of investment banking experience, with a strong focus on mergers & acquisitions and capital raising across Industrials, Education, Telecom, Cement, and Healthcare sectors. Prior to joining InCred Capital, he was part of the senior leadership team at MAPE Advisory Group for over a decade and has previously worked with Lazard, Ambit Capital, and Macquarie Capital.

His deal experience includes advising Veranda Learning on multiple acquisitions and its IPO, Emami on its bid for Paras Pharma, HeidelbergCement on the acquisitions of Mysore Cement and Indo Rama Cement, Italcementi on the acquisition of Sri Vishnu Cement along with an open offer, Bharti Airtel on the acquisitions of Hexacom India and the Spice Calcutta circle, as well as the sale of NLD rights to VSNL, Advent on its bid for Lafarge India.

He has also advised Jagdale Industries on the sale of its electrolyte drinks brand to Johnson & Johnson, promoters of Orissa Sponge on stake sales to Bhushan Steel and Monnet Ispat and on takeover defence, Fortis Healthcare on takeover defence and the sale of a minority stake to Khazanah, ICI India on the sale of its Nitrocellulose business to Actis and its rubber chemicals business, Jai Balaji Industries on the sale of its DI pipe unit and on QIP fund raising, Orbit Corporation and Ansal APIL on QIP-led equity fund raises, Walton Street Capital on raising a USD 500 million India-focused real estate fund, and on acquisition debt funding for the purchase of the RL Fine Chem API business.

Ashish Ambwani

Managing Director – Investment Banking

Ashish Ambwani has two decades of investment banking experience with a focus on cross-border M&A and Private Equity, and deep sector expertise across Consumption &Retail, Industrials and Digital businesses. He previously served as Director at Lazard for over 12 years and began his career at KPMG.

He has worked on numerous transactions including Osam Dairy’s sale to Dodla Dairy, Livpure’s capital raise from M&G Investments, QIMA’s acquisition of EFRAC Limited, Raymond Consumer Care’s FMCG sale to Godrej Consumer, IPO of Ethos Limited, Manohar Packaging’s sale to Parksons Packaging, MM Polytech’s sale to Huhtamaki, YY Inc.’s acquisition of Bigo, Kama Ayurveda’s fund raise and sale to Puig, Magnet360’s sale to Mindtree, Danone’s acquisition of Wockhardt nutrition assets, UCB’s sale of Indian brands to Dr Reddy’s, Sabero Organics’ sale to Coromandel, International Paper on its acquisition of AP Paper, Avantor on its acquisition of RFCL.

He holds an MBA from IIM Lucknow and a has a degree in Electrical & Electronics Engineering from NIT Trichy.

Jacob Mathew

Consultant- Investment Banking

Jacob Mathew brings over 25 years of experience in investment banking, private equity, and fundraising. He co-founded MAPE Advisory, a boutique investment bank focused on mid-market companies. Prior to MAPE, he was a Vice President (M&A) at Merrill Lynch India and played a key role in setting up the corporate finance practice at PwC India.

He has worked and led numerous transactions including the acquisition of Coats Viyella’s garment business by the AV Birla Group, the sale of Burnol and Coldarin brands, Dr Reddy’s buyout of American Remedies, and the sale of Diamond Dychem to Ciba AG. At MAPE, he led transactions across technology, telecommunications, consumer, healthcare, and retail sectors. His key clients include Coffee Day Enterprises, Strides, Igarashi Motors, J&J India, and Jyothi Labs.

He holds a PGDM from IIM Calcutta and is a Civil Engineer.

M Ramprasad

Consultant – Investment Banking

M Ramprasad has over 25 years of experience across investment banking, private equity, and fundraising. He co-founded MAPE Advisory, a boutique Indian investment bank focused on mid-market companies, which later merged with the Investment banking team at InCred in 2020. Prior to MAPE, he was a Senior Vice President at Merrill Lynch India, leading South India operations.

He has led marquee transactions for leading business groups including Tata Group, DuPont, ICICI Bank, Dr Reddy’s, and Sify, and at MAPE advised on landmark deals across manufacturing, infrastructure, and financial services. His key clients include Murugappa Group, ELGi Equipments, Curatio, Jyothi Labs, Karvy Financial Group, Star Health, and CRH Group.

He holds a PGDM from BIM Trichy and a degree in Chemistry.

Sanjay Singh

Head of Investment Banking – InCred Capital

Sanjay Singh is the Head of Investment Banking at InCred Capital, where he leads coverage across both advisory and equity capital markets. He brings over 20 years of experience across investment banking, strategy, and operations, with deep expertise in the pharmaceuticals and healthcare sectors.

Prior to joining InCred, he held leadership roles at BDA Partners as Head of India and Co-Head of Healthcare Asia, and at KPMG as Partner and Head of Life Sciences in India. He has also worked with Dr. Reddy’s Laboratories and Glenmark Pharmaceuticals.

His transaction experience includes advising Chemfield Cellulose on its divestment to Oji Holdings, Archimica S.p.A. on its acquisition by PI Industries, Synokem Pharmaceuticals on growth investment from TA Associates, Isagro SpA on the divestment of Isagro Asia Agrochemicals to PI Industries, SMT on its equity raise from Morgan Stanley Private Equity, Astec LifeSciences on the sale of equity to Godrej Agrovet and Nihon Nohyaku on its acquisition of Hyderabad Chemical Limited amongst others.

Sanjay holds an MBA from IIM Bangalore and a B Tech from IIT BHU.